Search results
Results from the WOW.Com Content Network
Description: United States Patent 6630507 "Cannabinoids as antioxidants and neuroprotectants" issued to The United States of America as represented by the Department of Health and Human Services
A patent applicant may include a copyright notice or mask work notice, but only if it also includes the following authorization, expressly permitting the reproduction of the patent: [9] A portion of the disclosure of this patent document contains material which is subject to (copyright or mask work) protection.
The issue of novelty often arises during patent examination, because of inadvertent and/or partial disclosures by inventors themselves prior to filing a patent application. [citation needed] Unlike the laws of most countries, the US patent law provides for a one-year grace period in cases of inventor's own prior disclosure. [28]
In Indonesia, the Patent Office (Direktorat Jenderal Kekayaan Intelektual, "Directorate General of Intellectual Property") is a governmental agency overseeing intellectual property rights (HKI). A public body carrying out this function has existed since Dutch colonial times.
E. W. Kemble's "Death's Laboratory" on the cover of Collier's (June 3, 1905). A patent medicine, also known as a proprietary medicine or a nostrum (from the Latin nostrum remedium, or "our remedy") is a commercial product advertised to consumers as an over-the-counter medicine, generally for a variety of ailments, without regard to its actual effectiveness or the potential for harmful side ...
The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act, is a 1984 United States federal law that established the modern system of generic drug regulation in the United States.
The reverse doctrine of equivalents is a legal doctrine of United States patent law, according to which a device that appears to literally infringe a patent claim, by including elements or limitations that correspond to each element or limitation of the patent claim, nonetheless does not infringe the patent, because the accused device operates on a different principle.
In other words, when an applicant files an application for a patent or a trademark in a foreign country member of the Union, the application receives the same treatment as if it came from a national of this foreign country. Furthermore, if the intellectual property right is granted (e.g. if the applicant becomes owners of a patent or of a ...